Ascendiant Capital

Ascendiant Capital raised its rating on PhotoMedex (NASDAQ: PHMD) from Buy to Strong Buy with a reiterated $18 price target. Ascendiant Capital noted, "Revenue was $56.7 MM (+63% yoy), which was below our and consensus estimates of $58.0 MM and $58.7 MM respectively. Pro forma revenue growth was...